GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 3, 2025, serves as a notification that GSK Plc has filed its 2024 Annual Report on Form 20-F with the SEC. The filing includes audited financial statements for the fiscal year ended December 31, 2024. GSK is a global biopharma company headquartered in London, United Kingdom.
Key Financial Metrics
The provided text is a cover announcement and does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. Investors must refer to the full 2024 Annual Report on Form 20-F for these metrics.
Material Changes
The filing text does not provide comparative financial data or details on material changes versus the prior period. Such information is contained within the referenced Form 20-F.
Guidance, Outlook, and Risks
The document includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Specific risk factors are referenced as being detailed under Item 3.D "Risk factors" in the 2024 Annual Report on Form 20-F. No specific guidance or management commentary on future performance is included in this text.
Key Facts for Investor Verification
- The 2024 Annual Report on Form 20-F is available online at annualreport.gsk.com and via the SEC website.
- A hard copy of the report and the Notice of Annual General Meeting will be available on or about March 24, 2025.
- Shareholders may request free hard copies of the audited financial statements through Computershare Investor Services (UK), J.P. Morgan Chase Bank (US), or the GSK Response Center (US).
- Specific financial results and risk details must be verified in the full Form 20-F document, as they are not summarized in this Form 6-K.